Promoter hypermethylation identifies progression risk in bladder cancer.

Promoter hypermethylation identifies progression risk in bladder cancer.

PURPOSE: New methods to accurately predict an individual tumor behavior are urgently required to improve the treatment of cancer. We previously found that promoter hypermethylation can be an accurate predictor of bladder cancer progression, but it is not cancer specific. Here, we investigate a pane...

وصف كامل

التفاصيل البيبلوغرافية
المؤلفون الرئيسيون:	Yates, DR, Rehman, I, Abbod, M, Meuth, M, Cross, S, Linkens, D, Hamdy, F, Catto, J
التنسيق:	Journal article
اللغة:	English
منشور في:	2007

مواد مشابهة

A gene promoter hypermethylation panel to detect transitional cell carcinoma of the bladder
حسب: Yates, DR, وآخرون
منشور في: (2006)

Promoter hypermethylation in circulating blood cells identifies prostate cancer progression.
حسب: Rouprêt, M, وآخرون
منشور في: (2008)

Promoter hypermethylation in circulating blood cells identifies prostate cancer progression
حسب: Roupret, M, وآخرون
منشور في: (2008)

Development of a prognostic marker panel in bladder cancer using aberrant promoter methylation
حسب: Catto, J, وآخرون
منشور في: (2007)

Comparative study of intelligent models for the prediction of bladder cancer progression.
حسب: Abbod, M, وآخرون
منشور في: (2006)

Neuro-fuzzy modeling: an accurate and interpretable method for predicting bladder cancer progression.
حسب: Catto, J, وآخرون
منشور في: (2006)

Comparing gene promoter methylation frequencies in urine from patients with bladder cancer with urine from non-cancerous young and elderly control patients
حسب: Yates, DR, وآخرون
منشور في: (2005)

Artificial intelligence for the prediction bladder cancer
حسب: Abbod, M, وآخرون
منشور في: (2004)

Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma.
حسب: Catto, J, وآخرون
منشور في: (2005)

Methylational urinalysis: a prospective study of bladder cancer patients and age stratified benign controls.
حسب: Yates, DR, وآخرون
منشور في: (2006)

Lactate dehydrogenase-B is silenced by promoter hypermethylation in human prostate cancer.
حسب: Leiblich, A, وآخرون
منشور في: (2006)

Lactate dehydrogenase-B is silenced by promoter hypermethylation in human prostate cancer
حسب: Catto, J, وآخرون
منشور في: (2006)

Improving gene array analysis: The application of artificial intelligence identifies novel biomarkers of non invasive papillary bladder cancer progression
حسب: Wild, P, وآخرون
منشور في: (2007)

Neurofuzzy modeling to determine recurrence risk following radical cystectomy for nonmetastatic urothelial carcinoma of the bladder.
حسب: Catto, J, وآخرون
منشور في: (2009)

The application of artificial intelligence to microarray data: identification of a novel gene signature to identify bladder cancer progression.
حسب: Catto, J, وآخرون
منشور في: (2010)

Predictive modeling in cancer: where systems biology meets the stock market.
حسب: Abbod, M, وآخرون
منشور في: (2009)

Artificial intelligence in predicting bladder cancer outcome: a comparison of neuro-fuzzy modeling and artificial neural networks.
حسب: Catto, J, وآخرون
منشور في: (2003)

Application of artificial intelligence to the management of urological cancer
حسب: Abbod, MF, وآخرون
منشور في: (2007)

Artificial intelligence re-analysis of gene array data identifies novel markers of urothelial cancer progression
حسب: Catto, J, وآخرون
منشور في: (2007)

Aberrant promoter methylation in pre-malignant and invasive tumours of the urinary bladder
حسب: Yates, D, وآخرون
منشور في: (2005)

Artificial intelligence technique for gene expression profiling of urinary bladder cancer
حسب: Abbod, M, وآخرون
منشور في: (2006)

Proteomics and immunohistochemistry identify loss of nucleophosmin (B23) expression in bladder transitional cell carcinomas
حسب: Ahmad, M, وآخرون
منشور في: (2003)

Artificial intelligence technique for gene expression profiling of urinary bladder cancer
حسب: Abbod, M, وآخرون
منشور في: (2006)

Artificial intelligence and bladder cancer arrays.
حسب: Wild, P, وآخرون
منشور في: (2007)

Genetic instability and transitional cell carcinoma of the bladder.
حسب: Catto, J, وآخرون
منشور في: (2004)

Hypermethylation of CpG islands and shores around specific microRNAs and mirtrons is associated with the phenotype and presence of bladder cancer.
حسب: Dudziec, E, وآخرون
منشور في: (2011)

PER3 promoter hypermethylation correlates to the progression of pan-cancer
حسب: Yaoxu Li, وآخرون
منشور في: (2024-10-01)

Differential expression of hMLH1 and hMSH2 is related to bladder cancer grade, stage and prognosis but not microsatellite instability.
حسب: Catto, J, وآخرون
منشور في: (2003)

Itraq-facilitated proteomic analysis of human prostate cancer cells identifies proteins associated with progression
حسب: Rehman, I, وآخرون
منشور في: (2008)

iTRAQ-facilitated proteomic analysis of human prostate cancer cells identifies proteins associated with progression.
حسب: Glen, A, وآخرون
منشور في: (2008)

Inactivation of the hypermethylated in cancer 1 tumour suppressor – not just a question of promoter hypermethylation?
حسب: M Jenal, وآخرون
منشور في: (2010-10-01)

Role of hypermethylated-lncRNAs in the prognosis of bladder cancer patients
حسب: Junhua Luo, وآخرون
منشور في: (2021-10-01)

Evidence for the early onset of aberrant promoter methylation in urothelial carcinoma.
حسب: Dhawan, D, وآخرون
منشور في: (2006)

Proteomic analysis of voided urine after prostatic massage from patients with prostate cancer: a pilot study.
حسب: Rehman, I, وآخرون
منشور في: (2004)

Hypermethylation at 45S rDNA promoter in cancers.
حسب: Trang Thi Quynh Tran, وآخرون
منشور في: (2025-01-01)

Hypermethylation at 45S rDNA promoter in cancers
حسب: Trang Thi Quynh Tran, وآخرون
منشور في: (2025-01-01)

Epigenetic changes in urothelial cancer: A feature of the invasive phenotype and a novel therapeutic target
حسب: Catto, J, وآخرون
منشور في: (2006)

Promoter hypermethylation-mediated inactivation of multiple Slit-Robo pathway genes in cervical cancer progression
حسب: Mansukhani Mahesh, وآخرون
منشور في: (2006-05-01)

Targeting chemotherapy to advanced bladder cancer patients most likely to benefit.
حسب: Catto, J, وآخرون
منشور في: (2010)

FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours.
حسب: van Oers, J, وآخرون
منشور في: (2009)